NCT03983018View on ClinicalTrials.gov

Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Schizophrenia Spectrum and Other Psychotic DisordersTreatment-resistant Schizophrenia
Interventions
DRUG

Rituximab

Infusion

Trial Locations (1)

70116

Region Örebro Län, Örebro

All Listed Sponsors
collaborator

Örebro University, Sweden

OTHER

lead

Region Örebro County

OTHER

NCT03983018 - Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) | Biotech Hunter | Biotech Hunter